ReviewJournal of advanced research2026
Unraveling the nexus in the neuro-neoplastic progression of colorectal cancer: Potential role of β2-adrenergic receptor (β2-AR).
Review in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Targeting β-Adrenergic Signaling in Colorectal Cancer: Molecular Mechanisms and Therapeutic Potential of β-Blockers.Cancers · 2026Review
- Targeting tumor-associated G-protein coupled receptors: beyond single-axis inhibition toward multidimensional regulation.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- The neuro-vascular-immune triad: the interactive network in the tumor microenvironment.Cell communication and signaling : CCS · 2026Review
- Neural-tumor crosstalk and molecular targeting: mechanisms and therapeutic implications in cancer neuroscience.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Mechanistic study of deoxycholic acid in colorectal cancer based on network toxicology and machine learning approaches.BMC pharmacology & toxicology · 2026Article
- Outer membrane vesicles fromFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies on the interaction of cancer cells with other cells (fibroblasts, endothelial cells, and immune cells) of the tumor microenvironment (TME) have led to the development of many novel targeted therapies. More recently, the notion that neuronal cells of the TME could impact various processes supporting cancer progression has gained momentum. Tumor-associated neurons release neurotransmitters into the TME that, in turn, bind to specific receptors on different target cells, supporting cancer progression. Furthermore, cancer cells secrete nerve growth factors and neurotropic factors that facilitate the growth of nerve fibers that innervate the tumor. In this regard, the beta 2-adrenergic receptors (β2-AR), which respond to neurotropic factors such as catecholamines, are highly expressed in cancer cells, including colorectal cancer (CRC). AIM OF REVIEW: Understanding the complexity of the neuronal-cancer axis and identifying targets for molecular therapy is essential. This review focuses on the role of β2-AR in neuro-neoplastic cell signaling during CRC progression and its clinical relevance to diagnosis, prognosis, and treatment. KEY SCIENTIFIC CONCEPTS OF REVIEW: The expression of β2-AR on CRC and various other cells of the colorectal TME, along with its responsiveness to agonists or antagonists, is of particular interest since targeting β2-AR and related pathways could curb CRC growth. In the current article, we provide an in-depth review of the possible central role of β2-AR in CRC cancer progression, with special reference to stress-induced activation of the nervous system, catecholamine release, hyperactivation of adrenergic signaling concerning the activation of downstream oncogenic pathways, immuno-modulation, and metastasis. The article also emphasizes the clinical significance of β2-AR expression, its potential as a diagnostic/prognostic biomarker, and the benefits of targeting (by repurposing β-blockers) β2-AR in combination therapies to improve the therapeutic efficacy of current treatment options and overall patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.